GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GENFIT S.A.

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 11, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2023:

• 147,812 shares

• €530 615.28

During the second half of 2023, total trading was:

• On the buy side: 1721,869 shares for a total amount of €5,726,529.19

• On the sell side: 1697,197 shares for a total amount of €5,640,811.12

During this same period, the number of trades were:

• On the buy side: 2,351

• On the sell side: 2,016

As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

• 27, 911 shares

• €769 849,43

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Today, GENFIT has a growing and diversified pipeline with programs at various development stages. The Company’s area of focus is Acute on Chronic Liver Failure (ACLF). Its ACLF franchise consists of five assets in development: VS-01, NTZ, SRT-015, CLM-022 and VS-02-HE. These are all based on differentiated mechanisms of action leveraging complementary pathways. Other assets target other life-threatening disease indications such as cholangiocarcinoma (CCA) and Urea Cycle Disorders (UCD)/Organic Acidemias (OA). GENFIT’s track record in bringing early-stage assets with high potential to late development and pre-commercialization stages is highlighted in the successful 52-week Phase 3 ELATIVE® trial evaluating elafibranor in PBC. Beyond therapeutics, GENFIT’s pipeline also includes a diagnostic franchise focused on Metabolic dysfunction-associated steatohepatitis (MASH) previously known as nonalcoholic steatohepatitis (NASH) and ammonia. GENFIT has facilities in Lille and Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s largest shareholders and holds 8% of the company’s share capital. For more information, visit www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, in relation to GENFIT’s research and development programs. The use of certain words, including “believe”, “potential,” “expect”, “target”, “may” and “will” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, potential commercial success of elafibranor if approved, exchange rate fluctuations, our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Main Risks and Uncertainties” of the Company’s 2022 Universal Registration Document filed with the AMF on April 18, 2023, which is available on the Company’s website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”) including the Company’s 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 and subsequent filings and reports filed with the AMF or SEC, including the Half-Year Business and Financial Report at June 30, 2023 or otherwise made public, by the Company. In addition, even if the Company’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACT

GENFIT | Investors

Tel: +33 3 2016 4000 | investors@genfit.com

GENFIT | Media

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

APPENDIX
H2 2023

		Buy side						Sell side
Date		Number of executions		Number of shares		Traded amounts in EUR		Number of executions		Number of shares		Traded amounts in EUR
TOTAL		2 351		1 721 869		5 726 529,19		2 016		1 697 197		5 640 811,12
03/07/2023		90		119123		417 548,75		64		113328		399 399,60
04/07/2023		61		91000		328 009,50		42		62066		224 907,32
05/07/2023		60		91863		329 731,21		49		93674		338 505,05
06/07/2023		36		56000		203 217,28		16		25999		95 160,50
07/07/2023		10		7501		26 953,64		23		34730		126 346,35
10/07/2023		15		9001		32 973,72		23		17501		64 973,69
11/07/2023		5		4501		16 721,22		17		9191		34 363,59
12/07/2023		15		10361		37 937,01		18		9101		33 486,22
13/07/2023		36		3884		14 279,99		15		6267		23 244,18
14/07/2023		15		7482		27 404,55		7		4722		17 378,47
17/07/2023		8		5304		19 425,26		10		5761		21 225,66
18/07/2023		6		2981		10 939,70		15		4644		17 150,94
19/07/2023		20		4979		18 285,58		7		1516		5 611,70
20/07/2023		10		9181		33 114,49		4		2801		10 153,68
21/07/2023		10		5001		17 866,07		4		5001		18 003,60
24/07/2023		14		11001		39 241,45		15		8001		28 728,63
25/07/2023		18		13311		46 865,10		7		6001		21 198,59
26/07/2023		21		12691		44 345,02		11		8001		28 203,53
27/07/2023		11		10001		34 643,46		13		6001		20 913,42
28/07/2023		20		18001		60 993,51		12		6002		20 416,88
31/07/2023		8		10001		33 533,45		7		2003		6 750,25
01/08/2023		10		5001		16 873,32		16		11001		37 473,26
02/08/2023		21		13605		45 217,71		8		5605		18 714,87
03/08/2023		4		4001		13 193,30		6		6022		20 123,66
04/08/2023		1		1		3,35		16		7980		27 073,03
07/08/2023		1		1		3,41		5		7001		24 263,44
08/08/2023		1		1		3,44		11		7001		24 433,42
09/08/2023		4		1001		3 463,48		3		501		1 738,48
10/08/2023		3		1801		6 135,48		6		4001		13 718,51
11/08/2023		5		4001		14 103,53		25		16901		60 314,09
14/08/2023		3		1001		3 453,46		1		1		3,46
15/08/2023		10		3002		10 212,35		3		360		1 256,40
16/08/2023		8		2300		7 709,51		1		1		3,37
17/08/2023		1		1		3,31		6		2001		6 673,31
18/08/2023		8		5318		17 579,39		6		5361		17 784,10
21/08/2023		11		10184		33 277,24		4		2291		7 422,91
22/08/2023		20		11001		35 043,25		12		9961		33 110,07
23/08/2023		10		7001		22 083,18		19		12001		38 595,70
24/08/2023		19		14001		44 713,17		16		7584		24 628,81
25/08/2023		5		2715		8 592,27		13		8005		25 609,76
28/08/2023		1		1		3,2		16		14414		46 640,97
29/08/2023		4		4501		14 898,31		14		15001		49 996,98
30/08/2023		17		9002		29 639,09		6		1501		5 058,35
31/08/2023		2		1500		4 875,05		7		3001		9 865,79
01/09/2023		4		1501		4 968,33		3		1501		4 998,33
04/09/2023		19		9002		29 616,58		13		4501		14 973,30
05/09/2023		17		5999		19 429,26		7		3000		9 787,47
06/09/2023		21		14287		45 364,08		10		5001		15 953,19
07/09/2023		10		9928		33 675,08		42		41594		142 039,35
08/09/2023		20		17200		61 385,25		12		17201		62 568,64
11/09/2023		15		11350		43 256,10		16		9350		36 214,98
12/09/2023		12		10467		38 788,82		5		2028		7 606,89
13/09/2023		16		8001		29 173,65		14		10001		36 948,69
14/09/2023		15		9001		33 113,78		12		7001		25 833,76
15/09/2023		16		7001		25 493,65		3		2001		7 343,67
18/09/2023		20		9501		33 486,65		1		1		3,63
19/09/2023		8		11557		39 525,06		1		1		3,49
20/09/2023		5		904		3 118,79		9		10001		34 765,98
21/09/2023		14		19842		67 125,09		5		1960		6 869,78
22/09/2023		28		17117		54 700,97		6		29958		95 766,14
25/09/2023		10		14001		43 463,30		2		358		1 159,92
26/09/2023		19		20001		59 993,00		51		68644		218 896,11
27/09/2023		25		15001		46 715,36		1		1		3,21
28/09/2023		16		16846		51 983,05		31		31848		98 878,80
29/09/2023		17		8617		26 973,54		19		11999		37 631,74
02/10/2023		37		19880		61 440,33		18		6496		20 281,23
03/10/2023		9		8001		23 882,99		7		2721		8 297,47
04/10/2023		1		1		2,93		1		1		2,93
05/10/2023		23		18720		55 269,68		21		20001		59 297,96
06/10/2023		20		10001		29 502,95		36		24001		71 203,05
09/10/2023		19		14001		42 443,05		34		15044		45 998,38
10/10/2023		42		22101		66 413,95		47		26002		78 445,95
11/10/2023		20		8547		27 024,76		28		17252		53 928,89
12/10/2023		11		10211		31 938,37		7		5001		15 683,14
13/10/2023		41		16441		50 597,67		9		6035		18 583,39
16/10/2023		8		6001		18 183,03		14		7967		24 289,47
17/10/2023		26		14246		43 329,07		28		14034		42 858,85
18/10/2023		32		13293		40 352,90		8		7878		24 076,59
19/10/2023		43		27901		81 730,12		20		10247		30 137,55
20/10/2023		7		5396		15 484,31		15		10292		29 964,54
23/10/2023		7		2202		6 419,84		7		2202		6 466,68
24/10/2023		30		14530		44 109,16		23		19612		59 457,90
25/10/2023		34		19473		57 263,67		11		7184		21 076,56
26/10/2023		13		10000		29 040,00		14		14818		43 434,37
27/10/2023		43		12561		37 911,23		21		13413		40 738,37
30/10/2023		15		17065		51 278,11		11		8001		24 133,02
31/10/2023		8		4002		12 165,96		9		8001		24 352,96
01/11/2023		22		17776		53 512,69		18		8847		26 791,72
02/11/2023		26		25501		78 420,42		38		40987		126 130,11
03/11/2023		21		11794		36 925,24		27		27380		86 190,87
06/11/2023		26		17273		53 180,63		7		4080		12 537,47
07/11/2023		8		4817		14 813,33		15		18010		56 002,28
08/11/2023		4		2157		6 772,98		3		2845		8 990,17
09/11/2023		15		7512		23 658,44		44		32668		104 008,05
10/11/2023		41		29520		90 918,06		11		10876		33 474,48
13/11/2023		1		1		3,08		18		15313		48 576,66
14/11/2023		59		41127		132 912,59		71		26459		86 146,54
15/11/2023		49		27766		86 897,86		14		12766		40 228,35
16/11/2023		22		8263		25 391,21		11		6183		19 158,83
17/11/2023		27		14427		44 149,51		16		11342		34 912,72
20/11/2023		3		1624		5 088,56		14		14812		46 415,33
21/11/2023		27		14385		44 637,52		3		1362		4 208,63
22/11/2023		7		2022		6 206,04		6		668		2 062,61
23/11/2023		20		9134		27 505,85		2		190		575,68
24/11/2023		33		19664		59 441,72		11		18962		57 887,76
27/11/2023		17		6269		18 744,18		8		2305		6 932,26
28/11/2023		13		8884		26 497,60		12		8832		26 533,98
29/11/2023		17		9905		29 557,31		10		4921		14 809,36
30/11/2023		9		9899		29 623,95		69		29899		90 496,80
01/12/2023		13		9744		29 170,13		7		6708		20 159,69
04/12/2023		22		9332		27 988,07		26		19224		58 211,62
05/12/2023		14		6439		19 131,30		10		5332		15 972,17
06/12/2023		13		8242		24 183,76		15		13993		41 480,57
07/12/2023		7		6855		20 627,17		25		35355		109 064,16
08/12/2023		36		18001		57 693,02		31		33001		105 578,78
11/12/2023		10		8501		27 695,75		15		13631		44 908,69
12/12/2023		33		15520		53 221,96		21		18663		63 337,74
13/12/2023		22		8274		28 875,68		25		11501		40 148,15
14/12/2023		21		10001		36 406,04		17		6001		21 868,54
15/12/2023		12		6001		21 778,59		9		3787		13 772,49
18/12/2023		22		12501		46 991,13		15		8715		32 859,38
19/12/2023		34		31865		115 748,98		17		19190		70 395,44
20/12/2023		15		18606		66 111,40		6		10160		36 298,02
21/12/2023		43		42128		144 507,04		15		19558		67 147,31
22/12/2023		25		14931		50 798,40		20		19222		66 259,39
27/12/2023		27		31000		109 565,47		33		40468		143 914,73
28/12/2023		12		12401		44 612,10		12		12037		43 542,28
29/12/2023		29		46000		164 321,20		18		16984		61 240,40

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com

Attachment

• GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial